LGALS3 and metabolic dysfunction-associated steatohepatitis: As a result, compounds like the galectin-3 inhibitor belapectin, which shows promise in preclinical mouse models, often fail to demonstrate robust efficacy in improving fibrosis in MASH patients [211].